Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009.
Identifieur interne : 000562 ( Main/Exploration ); précédent : 000561; suivant : 000563Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009.
Auteurs : Danuta M. Skowronski [Canada] ; Naveed Z. Janjua ; Gaston De Serres ; Travis S. Hottes ; James A. Dickinson ; Natasha Crowcroft ; Trijntje L. Kwindt ; Patrick Tang ; Hugues Charest ; Kevin Fonseca ; Jonathan B. Gubbay ; Nathalie Bastien ; Yan Li ; Martin PetricSource :
- BMJ (Clinical research ed.) [ 1756-1833 ] ; 2011.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (usage thérapeutique), Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Canada (épidémiologie), Enfant (MeSH), Enfant d'âge préscolaire (MeSH), Femelle (MeSH), Grippe humaine (prévention et contrôle), Grippe humaine (épidémiologie), Humains (MeSH), Jeune adulte (MeSH), Mâle (MeSH), Nourrisson (MeSH), Pandémies (prévention et contrôle), Résultat thérapeutique (MeSH), Sous-type H1N1 du virus de la grippe A (immunologie), Sujet âgé (MeSH), Surveillance sentinelle (MeSH), Vaccins antigrippaux (usage thérapeutique), Études cas-témoins (MeSH).
- MESH :
- immunologie : Sous-type H1N1 du virus de la grippe A.
- prévention et contrôle : Grippe humaine, Pandémies.
- usage thérapeutique : Adjuvants immunologiques, Vaccins antigrippaux.
- épidémiologie : Canada, Grippe humaine.
- Adolescent, Adulte, Adulte d'âge moyen, Enfant, Enfant d'âge préscolaire, Femelle, Humains, Jeune adulte, Mâle, Nourrisson, Résultat thérapeutique, Sujet âgé, Surveillance sentinelle, Études cas-témoins.
- Wicri :
- geographic : Canada.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (therapeutic use), Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Canada (epidemiology), Case-Control Studies (MeSH), Child (MeSH), Child, Preschool (MeSH), Female (MeSH), Humans (MeSH), Infant (MeSH), Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (therapeutic use), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Male (MeSH), Middle Aged (MeSH), Pandemics (prevention & control), Sentinel Surveillance (MeSH), Treatment Outcome (MeSH), Young Adult (MeSH).
- MESH :
- chemical , therapeutic use : Adjuvants, Immunologic, Influenza Vaccines.
- geographic , epidemiology : Canada.
- epidemiology : Influenza, Human.
- immunology : Influenza A Virus, H1N1 Subtype.
- prevention & control : Influenza, Human, Pandemics.
- Adolescent, Adult, Aged, Case-Control Studies, Child, Child, Preschool, Female, Humans, Infant, Male, Middle Aged, Sentinel Surveillance, Treatment Outcome, Young Adult.
Abstract
OBJECTIVE
To assess the effectiveness of the pandemic influenza A/H1N1 vaccine used in Canada during autumn 2009.
DESIGN
Test negative incident case-control study based on sentinel physician surveillance system.
SETTING
Community based clinics contributing to sentinel networks in British Columbia, Alberta, Ontario, and Quebec, Canada.
PARTICIPANTS
552 patients who presented to a sentinel site within seven days of onset of influenza-like illness during the primary analysis period between 8 November and 5 December 2009; participants were mostly (>80%) children and adults under 50 years old.
INTERVENTIONS
Monovalent AS03 adjuvanted pandemic influenza A/H1N1 vaccine as the predominant formulation (>95%) distributed in Canada.
MAIN OUTCOME MEASURES
Vaccine effectiveness calculated as 1-(odds ratio for influenza in vaccinated (received pandemic H1N1 vaccine at least two weeks before onset of influenza-like illness) versus unvaccinated participants), with adjustment for age, comorbidity, province, timeliness of specimen collection, and week of illness onset. Sensitivity analyses explored the influence of varying analysis periods between 1 November and 31 December, receipt of trivalent seasonal influenza vaccine, and restriction to participants without comorbidity.
RESULTS
During the primary analysis period, pandemic H1N1 was detected by reverse transcription polymerase chain reaction in 209/552 (38%) participants; rates were highest in children and young adults (40%) and lowest in people aged 65 or over (9%). Among the 209 cases, 35 (17%) reported comorbidity compared with 80/343 (23%) controls. Two (1%) cases had received pandemic H1N1 vaccine at least two weeks before the onset of illness, compared with 58/343 (17%) controls, all single dose. Adjusted vaccine effectiveness overall was 93% (95% confidence interval 69% to 98%). High estimates of vaccine protection-generally at least 90%-were maintained across most sensitivity analyses.
CONCLUSIONS
Although limited by a small number of vaccine failures, this study suggests that the monovalent AS03 adjuvanted vaccine used in Canada during autumn 2009 was highly effective in preventing medically attended, laboratory confirmed pandemic H1N1 illness, with reference in particular to a single dose in children and young adults.
DOI: 10.1136/bmj.c7297
PubMed: 21292718
PubMed Central: PMC3033439
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009.</title><author><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M" last="Skowronski">Danuta M. Skowronski</name><affiliation wicri:level="1"><nlm:affiliation>British Columbia Centre for Disease Control, Vancouver, BC, Canada. danuta.skowronski@bccdc.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>British Columbia Centre for Disease Control, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Janjua, Naveed Z" sort="Janjua, Naveed Z" uniqKey="Janjua N" first="Naveed Z" last="Janjua">Naveed Z. Janjua</name></author><author><name sortKey="De Serres, Gaston" sort="De Serres, Gaston" uniqKey="De Serres G" first="Gaston" last="De Serres">Gaston De Serres</name></author><author><name sortKey="Hottes, Travis S" sort="Hottes, Travis S" uniqKey="Hottes T" first="Travis S" last="Hottes">Travis S. Hottes</name></author><author><name sortKey="Dickinson, James A" sort="Dickinson, James A" uniqKey="Dickinson J" first="James A" last="Dickinson">James A. Dickinson</name></author><author><name sortKey="Crowcroft, Natasha" sort="Crowcroft, Natasha" uniqKey="Crowcroft N" first="Natasha" last="Crowcroft">Natasha Crowcroft</name></author><author><name sortKey="Kwindt, Trijntje L" sort="Kwindt, Trijntje L" uniqKey="Kwindt T" first="Trijntje L" last="Kwindt">Trijntje L. Kwindt</name></author><author><name sortKey="Tang, Patrick" sort="Tang, Patrick" uniqKey="Tang P" first="Patrick" last="Tang">Patrick Tang</name></author><author><name sortKey="Charest, Hugues" sort="Charest, Hugues" uniqKey="Charest H" first="Hugues" last="Charest">Hugues Charest</name></author><author><name sortKey="Fonseca, Kevin" sort="Fonseca, Kevin" uniqKey="Fonseca K" first="Kevin" last="Fonseca">Kevin Fonseca</name></author><author><name sortKey="Gubbay, Jonathan B" sort="Gubbay, Jonathan B" uniqKey="Gubbay J" first="Jonathan B" last="Gubbay">Jonathan B. Gubbay</name></author><author><name sortKey="Bastien, Nathalie" sort="Bastien, Nathalie" uniqKey="Bastien N" first="Nathalie" last="Bastien">Nathalie Bastien</name></author><author><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name></author><author><name sortKey="Petric, Martin" sort="Petric, Martin" uniqKey="Petric M" first="Martin" last="Petric">Martin Petric</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21292718</idno><idno type="pmid">21292718</idno><idno type="pmc">PMC3033439</idno><idno type="doi">10.1136/bmj.c7297</idno><idno type="wicri:Area/Main/Corpus">000567</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000567</idno><idno type="wicri:Area/Main/Curation">000567</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000567</idno><idno type="wicri:Area/Main/Exploration">000567</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009.</title><author><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M" last="Skowronski">Danuta M. Skowronski</name><affiliation wicri:level="1"><nlm:affiliation>British Columbia Centre for Disease Control, Vancouver, BC, Canada. danuta.skowronski@bccdc.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>British Columbia Centre for Disease Control, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Janjua, Naveed Z" sort="Janjua, Naveed Z" uniqKey="Janjua N" first="Naveed Z" last="Janjua">Naveed Z. Janjua</name></author><author><name sortKey="De Serres, Gaston" sort="De Serres, Gaston" uniqKey="De Serres G" first="Gaston" last="De Serres">Gaston De Serres</name></author><author><name sortKey="Hottes, Travis S" sort="Hottes, Travis S" uniqKey="Hottes T" first="Travis S" last="Hottes">Travis S. Hottes</name></author><author><name sortKey="Dickinson, James A" sort="Dickinson, James A" uniqKey="Dickinson J" first="James A" last="Dickinson">James A. Dickinson</name></author><author><name sortKey="Crowcroft, Natasha" sort="Crowcroft, Natasha" uniqKey="Crowcroft N" first="Natasha" last="Crowcroft">Natasha Crowcroft</name></author><author><name sortKey="Kwindt, Trijntje L" sort="Kwindt, Trijntje L" uniqKey="Kwindt T" first="Trijntje L" last="Kwindt">Trijntje L. Kwindt</name></author><author><name sortKey="Tang, Patrick" sort="Tang, Patrick" uniqKey="Tang P" first="Patrick" last="Tang">Patrick Tang</name></author><author><name sortKey="Charest, Hugues" sort="Charest, Hugues" uniqKey="Charest H" first="Hugues" last="Charest">Hugues Charest</name></author><author><name sortKey="Fonseca, Kevin" sort="Fonseca, Kevin" uniqKey="Fonseca K" first="Kevin" last="Fonseca">Kevin Fonseca</name></author><author><name sortKey="Gubbay, Jonathan B" sort="Gubbay, Jonathan B" uniqKey="Gubbay J" first="Jonathan B" last="Gubbay">Jonathan B. Gubbay</name></author><author><name sortKey="Bastien, Nathalie" sort="Bastien, Nathalie" uniqKey="Bastien N" first="Nathalie" last="Bastien">Nathalie Bastien</name></author><author><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name></author><author><name sortKey="Petric, Martin" sort="Petric, Martin" uniqKey="Petric M" first="Martin" last="Petric">Martin Petric</name></author></analytic><series><title level="j">BMJ (Clinical research ed.)</title><idno type="eISSN">1756-1833</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (therapeutic use)</term><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Canada (epidemiology)</term><term>Case-Control Studies (MeSH)</term><term>Child (MeSH)</term><term>Child, Preschool (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Infant (MeSH)</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza Vaccines (therapeutic use)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Pandemics (prevention & control)</term><term>Sentinel Surveillance (MeSH)</term><term>Treatment Outcome (MeSH)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (usage thérapeutique)</term><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Canada (épidémiologie)</term><term>Enfant (MeSH)</term><term>Enfant d'âge préscolaire (MeSH)</term><term>Femelle (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (épidémiologie)</term><term>Humains (MeSH)</term><term>Jeune adulte (MeSH)</term><term>Mâle (MeSH)</term><term>Nourrisson (MeSH)</term><term>Pandémies (prévention et contrôle)</term><term>Résultat thérapeutique (MeSH)</term><term>Sous-type H1N1 du virus de la grippe A (immunologie)</term><term>Sujet âgé (MeSH)</term><term>Surveillance sentinelle (MeSH)</term><term>Vaccins antigrippaux (usage thérapeutique)</term><term>Études cas-témoins (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Canada</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term><term>Pandemics</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term><term>Pandémies</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Canada</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Case-Control Studies</term><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Humans</term><term>Infant</term><term>Male</term><term>Middle Aged</term><term>Sentinel Surveillance</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Nourrisson</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Surveillance sentinelle</term><term>Études cas-témoins</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>To assess the effectiveness of the pandemic influenza A/H1N1 vaccine used in Canada during autumn 2009.</p></div><div type="abstract" xml:lang="en"><p><b>DESIGN</b></p><p>Test negative incident case-control study based on sentinel physician surveillance system.</p></div><div type="abstract" xml:lang="en"><p><b>SETTING</b></p><p>Community based clinics contributing to sentinel networks in British Columbia, Alberta, Ontario, and Quebec, Canada.</p></div><div type="abstract" xml:lang="en"><p><b>PARTICIPANTS</b></p><p>552 patients who presented to a sentinel site within seven days of onset of influenza-like illness during the primary analysis period between 8 November and 5 December 2009; participants were mostly (>80%) children and adults under 50 years old.</p></div><div type="abstract" xml:lang="en"><p><b>INTERVENTIONS</b></p><p>Monovalent AS03 adjuvanted pandemic influenza A/H1N1 vaccine as the predominant formulation (>95%) distributed in Canada.</p></div><div type="abstract" xml:lang="en"><p><b>MAIN OUTCOME MEASURES</b></p><p>Vaccine effectiveness calculated as 1-(odds ratio for influenza in vaccinated (received pandemic H1N1 vaccine at least two weeks before onset of influenza-like illness) versus unvaccinated participants), with adjustment for age, comorbidity, province, timeliness of specimen collection, and week of illness onset. Sensitivity analyses explored the influence of varying analysis periods between 1 November and 31 December, receipt of trivalent seasonal influenza vaccine, and restriction to participants without comorbidity.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>During the primary analysis period, pandemic H1N1 was detected by reverse transcription polymerase chain reaction in 209/552 (38%) participants; rates were highest in children and young adults (40%) and lowest in people aged 65 or over (9%). Among the 209 cases, 35 (17%) reported comorbidity compared with 80/343 (23%) controls. Two (1%) cases had received pandemic H1N1 vaccine at least two weeks before the onset of illness, compared with 58/343 (17%) controls, all single dose. Adjusted vaccine effectiveness overall was 93% (95% confidence interval 69% to 98%). High estimates of vaccine protection-generally at least 90%-were maintained across most sensitivity analyses.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Although limited by a small number of vaccine failures, this study suggests that the monovalent AS03 adjuvanted vaccine used in Canada during autumn 2009 was highly effective in preventing medically attended, laboratory confirmed pandemic H1N1 illness, with reference in particular to a single dose in children and young adults.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21292718</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-1833</ISSN><JournalIssue CitedMedium="Internet"><Volume>342</Volume><PubDate><Year>2011</Year><Month>Feb</Month><Day>03</Day></PubDate></JournalIssue><Title>BMJ (Clinical research ed.)</Title><ISOAbbreviation>BMJ</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009.</ArticleTitle><Pagination><MedlinePgn>c7297</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmj.c7297</ELocationID><ELocationID EIdType="pii" ValidYN="Y">bmj.c7297</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the effectiveness of the pandemic influenza A/H1N1 vaccine used in Canada during autumn 2009.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Test negative incident case-control study based on sentinel physician surveillance system.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Community based clinics contributing to sentinel networks in British Columbia, Alberta, Ontario, and Quebec, Canada.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">552 patients who presented to a sentinel site within seven days of onset of influenza-like illness during the primary analysis period between 8 November and 5 December 2009; participants were mostly (>80%) children and adults under 50 years old.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Monovalent AS03 adjuvanted pandemic influenza A/H1N1 vaccine as the predominant formulation (>95%) distributed in Canada.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Vaccine effectiveness calculated as 1-(odds ratio for influenza in vaccinated (received pandemic H1N1 vaccine at least two weeks before onset of influenza-like illness) versus unvaccinated participants), with adjustment for age, comorbidity, province, timeliness of specimen collection, and week of illness onset. Sensitivity analyses explored the influence of varying analysis periods between 1 November and 31 December, receipt of trivalent seasonal influenza vaccine, and restriction to participants without comorbidity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During the primary analysis period, pandemic H1N1 was detected by reverse transcription polymerase chain reaction in 209/552 (38%) participants; rates were highest in children and young adults (40%) and lowest in people aged 65 or over (9%). Among the 209 cases, 35 (17%) reported comorbidity compared with 80/343 (23%) controls. Two (1%) cases had received pandemic H1N1 vaccine at least two weeks before the onset of illness, compared with 58/343 (17%) controls, all single dose. Adjusted vaccine effectiveness overall was 93% (95% confidence interval 69% to 98%). High estimates of vaccine protection-generally at least 90%-were maintained across most sensitivity analyses.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although limited by a small number of vaccine failures, this study suggests that the monovalent AS03 adjuvanted vaccine used in Canada during autumn 2009 was highly effective in preventing medically attended, laboratory confirmed pandemic H1N1 illness, with reference in particular to a single dose in children and young adults.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Skowronski</LastName><ForeName>Danuta M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>British Columbia Centre for Disease Control, Vancouver, BC, Canada. danuta.skowronski@bccdc.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janjua</LastName><ForeName>Naveed Z</ForeName><Initials>NZ</Initials></Author><Author ValidYN="Y"><LastName>De Serres</LastName><ForeName>Gaston</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Hottes</LastName><ForeName>Travis S</ForeName><Initials>TS</Initials></Author><Author ValidYN="Y"><LastName>Dickinson</LastName><ForeName>James A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Crowcroft</LastName><ForeName>Natasha</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Kwindt</LastName><ForeName>Trijntje L</ForeName><Initials>TL</Initials></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Charest</LastName><ForeName>Hugues</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Fonseca</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Gubbay</LastName><ForeName>Jonathan B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Bastien</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Petric</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ</MedlineTA><NlmUniqueID>8900488</NlmUniqueID><ISSNLinking>0959-8138</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C556153">pandemrix</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>BMJ. 2011;342:d545</RefSource><PMID Version="1">21303882</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018571" MajorTopicYN="N">Sentinel Surveillance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21292718</ArticleId><ArticleId IdType="pmc">PMC3033439</ArticleId><ArticleId IdType="doi">10.1136/bmj.c7297</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bull World Health Organ. 1985;63(6):1055-68</Citation><ArticleIdList><ArticleId IdType="pubmed">3879673</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2011 Jan;8(1):e1000388</Citation><ArticleIdList><ArticleId IdType="pubmed">21379316</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 1994 Aug;12(11):993-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7975853</ArticleId></ArticleIdList></Reference><Reference><Citation>Can Commun Dis Rep. 2005 Sep 15;31(18):181-91</Citation><ArticleIdList><ArticleId IdType="pubmed">16669132</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 Apr 12;25(15):2842-51</Citation><ArticleIdList><ArticleId IdType="pubmed">17081662</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2009 Jan 15;199(2):168-79</Citation><ArticleIdList><ArticleId IdType="pubmed">19086914</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Epidemiol. 2009 Jun;19(6):432-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19460673</ArticleId></ArticleIdList></Reference><Reference><Citation>Wkly Epidemiol Rec. 2010 Mar 5;85(10):81-92</Citation><ArticleIdList><ArticleId IdType="pubmed">20210260</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Infect Dis. 2010;10:71</Citation><ArticleIdList><ArticleId IdType="pubmed">20236548</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2010 Apr;7(4):e1000258</Citation><ArticleIdList><ArticleId IdType="pubmed">20386731</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2010 May 6;15(18). pii: 19561</Citation><ArticleIdList><ArticleId IdType="pubmed">20460094</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2010;340:c2649</Citation><ArticleIdList><ArticleId IdType="pubmed">20508026</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Technol Assess. 2010 Jul;14(34):313-46</Citation><ArticleIdList><ArticleId IdType="pubmed">20630126</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2010 Jul;4(4):171-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20629771</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Bastien, Nathalie" sort="Bastien, Nathalie" uniqKey="Bastien N" first="Nathalie" last="Bastien">Nathalie Bastien</name><name sortKey="Charest, Hugues" sort="Charest, Hugues" uniqKey="Charest H" first="Hugues" last="Charest">Hugues Charest</name><name sortKey="Crowcroft, Natasha" sort="Crowcroft, Natasha" uniqKey="Crowcroft N" first="Natasha" last="Crowcroft">Natasha Crowcroft</name><name sortKey="De Serres, Gaston" sort="De Serres, Gaston" uniqKey="De Serres G" first="Gaston" last="De Serres">Gaston De Serres</name><name sortKey="Dickinson, James A" sort="Dickinson, James A" uniqKey="Dickinson J" first="James A" last="Dickinson">James A. Dickinson</name><name sortKey="Fonseca, Kevin" sort="Fonseca, Kevin" uniqKey="Fonseca K" first="Kevin" last="Fonseca">Kevin Fonseca</name><name sortKey="Gubbay, Jonathan B" sort="Gubbay, Jonathan B" uniqKey="Gubbay J" first="Jonathan B" last="Gubbay">Jonathan B. Gubbay</name><name sortKey="Hottes, Travis S" sort="Hottes, Travis S" uniqKey="Hottes T" first="Travis S" last="Hottes">Travis S. Hottes</name><name sortKey="Janjua, Naveed Z" sort="Janjua, Naveed Z" uniqKey="Janjua N" first="Naveed Z" last="Janjua">Naveed Z. Janjua</name><name sortKey="Kwindt, Trijntje L" sort="Kwindt, Trijntje L" uniqKey="Kwindt T" first="Trijntje L" last="Kwindt">Trijntje L. Kwindt</name><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name><name sortKey="Petric, Martin" sort="Petric, Martin" uniqKey="Petric M" first="Martin" last="Petric">Martin Petric</name><name sortKey="Tang, Patrick" sort="Tang, Patrick" uniqKey="Tang P" first="Patrick" last="Tang">Patrick Tang</name></noCountry><country name="Canada"><noRegion><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M" last="Skowronski">Danuta M. Skowronski</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeCanadaV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000562 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000562 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeCanadaV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21292718
|texte= Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21292718" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV4
| This area was generated with Dilib version V0.6.35. |  |